Innoviva, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45781M1018
USD
21.91
-0.15 (-0.68%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Keros Therapeutics, Inc.
Ligand Pharmaceuticals, Inc.
Innoviva, Inc.
ImmunityBio, Inc.
Ardelyx, Inc.
MannKind Corp.
Revance Therapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Morphic Holding, Inc.
ACELYRIN, Inc.
EQRx, Inc.

Why is Innoviva, Inc. ?

1
High Management Efficiency with a high ROCE of 30.79%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.93 times
3
Positive results in Sep 25
  • OPERATING CASH FLOW(Y) Highest at USD 201.66 MM
  • NET PROFIT(Q) At USD 32.68 MM has Grown at 339.19%
  • DEBT-EQUITY RATIO (HY) Lowest at -27.14 %
4
With ROCE of 22.85%, it has a very attractive valuation with a 2.82 Enterprise value to Capital Employed
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 25.58%, its profits have risen by 21.7% ; the PEG ratio of the company is 0.8
5
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Market Beating performance in long term as well as near term
  • Along with generating 25.58% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Innoviva, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Innoviva, Inc. for you?

Low Risk, High Return

Absolute
Risk Adjusted
Volatility
Innoviva, Inc.
26.79%
1.28
28.17%
S&P 500
14.9%
0.77
19.29%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
3.66%
EBIT Growth (5y)
-11.54%
EBIT to Interest (avg)
12.42
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.31
Tax Ratio
28.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
30.79%
ROE (avg)
41.84%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.33
EV to EBIT
12.36
EV to EBITDA
9.97
EV to Capital Employed
2.82
EV to Sales
5.16
PEG Ratio
0.76
Dividend Yield
NA
ROCE (Latest)
22.85%
ROE (Latest)
14.23%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 201.66 MM

NET PROFIT(Q)

At USD 32.68 MM has Grown at 339.19%

DEBT-EQUITY RATIO (HY)

Lowest at -27.14 %

CASH AND EQV(HY)

Highest at USD 1,030.83 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.54 times

NET SALES(Q)

Highest at USD 111.26 MM

EPS(Q)

Highest at USD 1.08

-4What is not working for the Company
RAW MATERIAL COST(Y)

Grown by 13.73% (YoY

OPERATING PROFIT(Q)

Lowest at USD 44.68 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 40.16 %

PRE-TAX PROFIT(Q)

Lowest at USD 35.56 MM

Here's what is working for Innoviva, Inc.

Net Profit
At USD 32.68 MM has Grown at 339.19%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Cash Flow
Highest at USD 201.66 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio
Lowest at -27.14 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales
Highest at USD 111.26 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

EPS
Highest at USD 1.08
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv
Highest at USD 1,030.83 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio
Highest at 2.54 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Depreciation
Highest at USD 10.11 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Innoviva, Inc.

Operating Profit
Lowest at USD 44.68 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin
Lowest at 40.16 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
Lowest at USD 35.56 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Raw Material Cost
Grown by 13.73% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales